From hepatitis C virus immunoproteomics to rheumatology via cross-reactivity in one table.

@article{Kanduc2019FromHC,
  title={From hepatitis C virus immunoproteomics to rheumatology via cross-reactivity in one table.},
  author={Darja Kanduc},
  journal={Current Opinion in Rheumatology},
  year={2019}
}
  • D. Kanduc
  • Published 1 September 2019
  • Medicine
  • Current Opinion in Rheumatology
PURPOSE OF REVIEW To give an overview of molecular and immunologic data that link hepatitis C virus (HCV) infection to rheumatic diseases in the human host. RECENT FINDINGS A high level of peptide sharing exists between immunopositive HCV epitopes and human proteins that, when altered, associate with rheumatic manifestations. SUMMARY The findings suggest the involvement of HCV infection in the induction of most rheumatic diseases via a mechanism of autoimmune cross-reactivity. 
From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity
TLDR
This study warns that using entire antigens in anti- EBV immunotherapies can associate with autoimmune manifestations and further supports the concept of peptide uniqueness for designing safe and effective anti-EBV immuntherapies.
Immunobiology: on the inexistence of a negative selection process
TLDR
The data show that a negative selection of self-reactive lymphocytes does not exist, demonstrate the essentially pathogenic nature of the immune response, and reveal the inconsistency of an immune system conceived as capable of discerning and reacting against any and all foreign sequences/structures.
Lack of Molecular Mimicry between Nonhuman Primates and Infectious Pathogens: The Possible Genetic Bases
  • D. Kanduc
  • Medicine
    Global medical genetics
  • 2021
TLDR
Analysis of proteomes from Ebola virus, Francisella tularensis, human immunodeficiency virus-1 (HIV-1), Toxoplasma gondii, Variola virus, and Yersinia pestis confirms that heptapeptide overlap is high between pathogens and Homo sapiens, but not between pathogens or primates, and indicates the zero/low level of molecular mimicry between infectious agents and primates.
Medical, Genomic, and Evolutionary Aspects of the Peptide Sharing between Pathogens, Primates, and Humans
Comparing mammalian proteomes for molecular mimicry with infectious pathogens highlights the highest levels of heptapeptide sharing between pathogens and human, murine, and rat proteomes, while the
Human Codon Usage: The Genetic Basis of Pathogen Latency
  • D. Kanduc
  • Biology, Medicine
    Global medical genetics
  • 2021
TLDR
Immunologically, this study warns that using codon optimization methodologies can (re)activate, potentiate, and immortalize otherwise quiescent, asymptomatic pathogens, thus leading to uncontrollable pandemics.
Hydrophobicity and the Physico-Chemical Basis of Immunotolerance
  • D. Kanduc
  • Chemistry, Medicine
    Pathobiology
  • 2020
This study analyzes the primary electrostatic interaction between the membrane-bound B-cell receptor and antigen peptide determinants, and identifies peptide frequency and hydrophobicity as the main

References

SHOWING 1-10 OF 49 REFERENCES
Uncommon immune-mediated extrahepatic manifestations of HCV infection
TLDR
Both common and uncommon extrahepatic manifestations of chronic hepatitis C are expected to no longer constitute a matter of comorbidity in the course of HCV infection.
Peptide cross-reactivity: the original sin of vaccines.
  • D. Kanduc
  • Biology, Medicine
    Frontiers in bioscience
  • 2012
TLDR
The present study recapitulates the significance of cross-reactivity from the molecular mimicry hypothesis to the phenomenon of microbial immunoevasion, and conclusively indicates sequence uniqueness as a basic criterion for designing effective vaccines exempt from autoimmuneCross-reactions.
Anti-MDA5 Antibody Spectrum in Western World
TLDR
A review will highlight the clinical significance of anti-MDA5 autoantibodies in Caucasian DM patients and define a unique phenotype among patients with dermatomyositis (DM).
Considering hepatitis C virus infection as a systemic disease
TLDR
The development of highly effective direct‐acting antiviral agents to treat HCV infection presented an opportunity to improve the HCV care cascade with the eradication of HCV in most infected patients and by reducing the burden of both hepatic and extrahepatic complications.
Relationships between autoantibody responses to deletion mutants of Ki antigen and clinical manifestations of lupus.
TLDR
Ki antigen contains multiple epitopes recognized by autoimmune sera, which revealed distinctive immune responses, associated with certain clinical subtypes of systemic lupus erythematosus.
Polyautoimmunity in rheumatological conditions
TLDR
This analysis summarizes an estimated prevalence of PA in the most common rheumatic diseases, the presumable risk factors for PA and influence of concomitant diseases on the course of disease.
Chronic hepatitis C viral infection among SLE patients: the significance of coexistence
TLDR
Patients with SLE have a greater proportion of chronic HCV infection than matched controls, and a significant association was also observed among patients of higher socioeconomic status.
Mechanistic immunological based classification of rheumatoid arthritis.
TLDR
A mixed innate and adaptive immunopathogenesis may be the key to understanding severe disease flares, resistant disease subsets that are unresponsive to standard therapy and for therapies that target the autoinflammatory component of disease that are not currently considered by expert therapeutic recommendations.
Cathepsin G and Its Role in Inflammation and Autoimmune Diseases.
  • Siming Gao
  • Medicine, Biology
    Archives of rheumatology
  • 2018
TLDR
This is the first study providing important information about cathepsin G in the pathogenesis of autoimmune diseases and suggesting that cathePSin G may be a new biomarker or treatment target.
Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
TLDR
Rheumatic IRAEs should be kept in mind during the follow-up and evaluation of patients treated with PD-1 inhibitors, and the concomitant development of symptomatic inflammatory myositis with fasciitis in lower extremities appears to be a new adverse effect of anti-PD-1 immunotherapy.
...
1
2
3
4
5
...